Cerus (CERS) Receives “Hold” Rating from BTIG Research
CERS has been the topic of several other research reports. Cantor Fitzgerald restated a buy rating and issued a $5.00 price objective on shares of Cerus in a research note on Tuesday, January 23rd. Zacks Investment Research downgraded shares of Cerus from a hold rating to a sell rating in a research note on Tuesday, January 30th. Robert W. Baird restated a buy rating and issued a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. BidaskClub downgraded shares of Cerus from a hold rating to a sell rating in a research note on Tuesday, December 12th. Finally, ValuEngine upgraded shares of Cerus from a strong sell rating to a sell rating in a research note on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $5.00.
Shares of Cerus (NASDAQ:CERS) opened at $5.13 on Friday. The stock has a market cap of $638.25, a price-to-earnings ratio of -9.16 and a beta of 2.16. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.89 and a quick ratio of 3.26. Cerus has a 52 week low of $1.93 and a 52 week high of $5.43.
In other Cerus news, CEO William Mariner Greenman sold 7,735 shares of Cerus stock in a transaction on Monday, March 12th. The shares were sold at an average price of $4.80, for a total transaction of $37,128.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 14,381 shares of company stock worth $69,685 in the last quarter. Corporate insiders own 7.40% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. BB&T Securities LLC acquired a new stake in Cerus during the third quarter worth $100,000. Teacher Retirement System of Texas acquired a new stake in Cerus during the fourth quarter worth $126,000. Voya Investment Management LLC boosted its stake in Cerus by 22.0% during the second quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after buying an additional 10,570 shares in the last quarter. Turner Investments LLC acquired a new stake in Cerus during the third quarter worth $177,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Cerus during the fourth quarter worth $197,000. Hedge funds and other institutional investors own 56.27% of the company’s stock.
WARNING: “Cerus (CERS) Receives “Hold” Rating from BTIG Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/03/14/cerus-cers-receives-hold-rating-from-btig-research.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.